Functionalized NaA nanozeolites labeled with 224,225Ra for targeted alpha therapy
Source abstract
Abstract
The 223 Ra, 224 Ra, and 225 Ra radioisotopes exhibit very attractive nuclear properties for application in radionuclide therapy. Unfortunately the lack of appropriate bifunctional ligand for radium is the reason why these radionuclides have not found application in receptor-targeted therapy. In the present work, the potential usefulness of the NaA nanozeolite as a carrier for radium radionuclides has been studied. 224 Ra and 225 Ra, α-particle emitting radionuclides, have been absorbed in the nanometer-sized NaA zeolite (30–70 nm) through simple ion exchange. 224,225 Ra-nanozeolites exhibited very high stability in solutions containing physiological salt, EDTA, amino acids, and human serum. To make NaA nanozeolite particles dispersed in water their surface was modified with a silane coupling agent containing poly(ethylene glycol) molecules. This functionalization approach let us covalently attach a biomolecule to the NaA nanozeolite surface.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Radiation Therapy and Dosimetry · Boron Compounds in Chemistry · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A (2005) Production of Ac-225 from Th-229 for thargeted alpha therapy. Anal Chem 77:6288–629110.1021/ac0580114 ↗
2. Boyle P, Levin B (2008) World Cancer Report 2008, IARC Press, International Agency for Research on Cancer, Lyon
3. Carlsson J, Aronsson EF, Hietala SA, Stigbrand T, Tennvall J (2003) Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66:107–11710.1016/S0167-8140(02)00374-2 ↗
4. Carmaliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 42:249–25710.1038/35025220 ↗
5. Chanda N, Kattumuri V, Shukla R, Zambre A, Kattia K, Upendran A, Kulkarni RR, Kann P, Fent GM, Casteel SW, Smith CJ, Boote E, Robertson JD, Cutler C, Lever JR, Katti KV, Kannan R (2010) Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci USA 107:8760–876510.1073/pnas.1002143107 ↗
6. Cho Y, Park S, Han T, Son D, Park J, Oh S, Moon D, Cho K, Ahn C, Byun Y, Kim IS, Kwon IC, Kim SY (2007) In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 28:1236–124710.1016/j.biomaterials.2006.10.002 ↗
7. Cullity BD (1956) Diffraction I: the directions of diffracted beams. In: elements of X-ray diffraction. Addison-Wesley Publishing Company, Massachusetts, pp 78–102
8. Cutler CS, Hennkens HM, Sisay N, Huclier-Markai S, Jurisson SS (2013) Radiometals for combined imaging and therapy. Chem Rev 113:858–88310.1021/cr3003104 ↗
9. Gramlich V, Meier WMZ (1971) The crystal structure of hydrated NaA: a detailed refinement of a pseudosymmetric zeolite structure. Kristallografiya 133:134–14910.1524/zkri.1971.133.133.134 ↗
10. Hamoudeh M, Kamleh MA, Diab R, Fessi H (2008) Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 60:1329–134610.1016/j.addr.2008.04.013 ↗
11. Henriksen G, Hoff P, Larsen RH (2002) Evaluation of potential chelating agents for radium. Appl Radiat Isot 56:667–67110.1016/S0969-8043(01)00282-2 ↗
12. Henriksen G, Schoultz BW, Michaelsenc TE, Bruland ØS, Larsen RH (2004) Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides. Nucl Med Biol 31:441–44910.1016/j.nucmedbio.2003.11.004 ↗
13. Hermanson GT (2008) Silane reaction strategies. In: Kiefhaber T (ed) Bioconjugate techniques, 2nd edn. Academic Press, San Diego, pp 565–567
14. Hong H, Zhang Y, Sun J, Cai W (2009) Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 4:399–41310.1016/j.nantod.2009.07.001 ↗
15. Hu Y, Liu Ch, Hang Y, Ren N, Ren Y, Tang Y (2009) Microwave-assisted hydtothermal synthesis of nanozeolites with controllable size. Microporus Mesoporus Mater 19:306–31410.1016/j.micromeso.2008.11.005 ↗
16. Kairem K, Erba P, Bergstöm K, Pauwels EKJ (2008) Nanoparticles in Cancer. Curr Radiopharm 1:30–3610.2174/1874471010801010030 ↗
17. Kucka J, Hruby M, Konak C, Kozempel J, Lebeda O (2006) Astatination of nanoparticles containing silver as possible carriers of 211At. Appl Radiat Isot 64:201–20610.1016/j.apradiso.2005.07.021 ↗
18. Longmire M, Choyke PL, Kobayashi H (2008) Dendrimer-based contrast agents for molecular imaging. Curr Top Med Chem 8:1180–118610.2174/156802608785849021 ↗
19. Luk BT, Fang RH, Zhang L (2012) Lipid- and polymer- based nanostructures for cancer theranostic. Theranostics 2:1117–112610.7150/thno.4381 ↗
20. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25:1341–135110.1007/s002590050306 ↗
21. Narbutt J, Bilewicz A (1998) Gamma emmiting radiotracers 224Ra, 212Pb and 212Bi from natural thorium. Appl Radiat Isot 49:89–9110.1016/S0969-8043(97)00234-0 ↗
22. Neves M, Kling A, Oliveira AJ (2005) Radionuclides used for therapy and suggestion for new candidates. Radioanal Nucl Chem 266:377–38410.1007/s10967-005-0920-5 ↗
23. Patel D, Kell A, Simard B, Deng JX, Xiang B, Lin HY, Gruwel M, Tian GH (2010) Cu2+-labeled, SPION loaded porous silica nanoparticles for cell labeling and multifunctional imaging probes. Biomaterials 31:2866–287310.1016/j.biomaterials.2009.12.025 ↗
24. Patt M, Schildan A, Habermann B, Mishchenko O, Patt JT, Sabri O (2010) 18F- and 11C-labelling of quantum dots with n.c.a.[18F]fluoroethyltosylate and [11C]methyliodide: a feasibility study. J Radioanal Nucl Chem 283:487–49110.1007/s10967-009-0356-4 ↗
25. Reichenberg D (1966) Ion exchange selectivity. In: Marinsky JA, Dekker M (eds) Ion exchange, vol 1. Cornell University, New York, pp 227–276
26. Schubiger PA, Alberto R, Smith A (1997) Vehicles, chelators, and radionuclides: choosing the building blocks of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 7:165–17910.1021/bc950097s ↗
27. Sherry HS (1969) The ion exchange properties of zeolites. In: Marinsky JA, Dekker M (eds) Ion exchange, vol 2. Cornell University, New York, pp 89–131
28. Ting G, Chang Ch-H, Wang H-E, Lee T-W (2010) Nanotargeted radionuclides for cancer nuclear imaging and internal therapy. J Biomed Biotechnol 2010:1–1710.1155/2010/953537 ↗
29. Tsotsalas MM, Kopka K, Luppi G, Wagner S, Law MP, Schaefers M, De Cola L (2010) Encapsulating 111In in nanocontainers for scintigraphic imaging: synthesis, characterization, and in vivo biodistribution. ACS Nano 4:342–34810.1021/nn901166u ↗
30. Volkert WA, Hoffman TJ (1998) Therapeutic radiopharmaceuticals. Chem Rev 9:2269–2292
31. Wang H, Holmberg BA, Yan Y (2002) Homogenious polimer—zeolite nanocomposite mambranes by incorporating dispersible template removed zeolite nanocrystals. J Mater Chem 12:3640–364310.1039/B207394C ↗
32. Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, Rondinone AJ, Standaert RF, Mirzadeh S (2011) LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. Bioconjug Chem 22:766–77610.1021/bc100574f ↗
33. Zielinska B, Apostolidis C, Bruchertseifer F, Morgenstern A (2007) An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Solv Extr Ion Exch 25:339–34910.1080/07366290701285108 ↗
34. Zoller F, Eisenhut M, Haberkorn U, Mier W (2009) Endoradiotherapy in cancer treatment—basic concepts and future trends. Eur J Pharmacol 625:55–6210.1016/j.ejphar.2009.05.035 ↗